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 •  A literature search was 
completed
 •  National guidelines for VTE 
management were reviewed 
and compared
 •  Guidelines were presented 
to Lehigh Valley Health  
Network’s (LVHN) Cancer 
Committee
 •  Standard parameter for 
anticoagulant holds in the 
thrombocytopenic oncology 
patient was established 
   −  Unless contraindicated, 
anticoagulants can be safely 
administered to oncology 
patients with a platelet 
count of 50,000/ml or 
higher
© 2017 Lehigh Valley Health NetworkTo fill a gap in knowledge regarding proper 
anticoagulant dosing and administration in the 
thrombocytopenic oncology patient     
 •  Venous thromboembolism (VTE) is defined as 
the development of a thrombus in the form of 
a deep vein thrombosis (DVT), a pulmonary 
embolism (PE), or a combination thereof 
(McCance et al., 2010).
 •  Due to the hypercoagulable state that occurs 
with malignancy, oncology patients are 4-7 
times more likely to develop VTE than the 
general population 
 •  VTE coupled with thrombocytopenia, a 
common toxicity experienced by patients 
undergoing chemotherapy or radiation, can 
make VTE management challenging
 •  Risks of anticoagulant administration versus 
anticoagulant holds during thrombocytopenia 
must be considered to ensure patient safety   
 •  Education on VTE management in the oncology population was assigned to 
inpatient oncology nurses via LVHN’s online learning system
 •  Nurses have voiced their appreciation for the education, review of guidelines, and 
establishment of a standard parameter for anticoagulant holds
 •  The education has led to decreased confusion over when to administer versus hold 
anticoagulants during thrombocytopenia
EVALUATION
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Comparison of Risk Assessment Tools
Assessment Tool Population Validated In
Caprini Risk Assessment Model (RAM) •  Surgical patients
• Gynecologic oncology patients
Padua Risk Assessment Model (RAM) •  Hospitalized medical patients
Multiple Myeloma Risk Assessment Model (RAM) 
(Thalidomide, Lenalidomide, Pomalidomide) • Multiple Myeloma patients
Khorana Predictive Model for Chemotherapy-
Associated VTE •  Surgical patients
Comparison of Guidelines & Current Recommendations
























in eye or vital 
organs, hgb 
drop of 2gm/
dL in 24 hours
Platelets 
<20,000/ml
INTERVENTIONS DISCUSSIONSIGNIFICANCE & 
BACKGROUND  •  Proper VTE management in the oncology 
population can lead to:
   −  Decreased morbidity and mortality
   −  Reduced costs associated with VTE
   −  Positively impact quality of life and reduce 
chances of future VTE recurrence
   −  Decrease the overall incidence of VTE in the 
oncology population
  •  Assessment and evaluation of VTE risk in 
oncology patients is essential
 •  Plans to implement a validated VTE risk 
assessment tool into EPIC are underway at 
LVHN
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